REFERENCES
Abuhammad, S., Alzoubi, K.H., Khabour, O.F., Hamaideh, S., Khasawneh, B. (2023). Sleep quality and sleep patterns among recovered individuals during post-COVID-19 among Jordanian: a cross-sectional national study.Medicine (Baltimore ), 102(3), e32737. doi: 10.1097/MD.0000000000032737
Avedisova, A.S., Zaharova, K.V., Marychev, M.P. (2013). The results of observational study JAZZ – the efficacy of agomelatine (Valdoxan) in the treatment of patients with anxious depression as part of major depressive disorders. Psychiatr Psychopharmacother , 6, 14-22.
Başol, N., Erbaş, O., Çavuşoğlu, T., Meral, A., Ateş, U. (2016). Beneficial effects of agomelatine in experimental model of sepsis-related acute kidney injury. Ulus Travma Acil Cerrahi Derg , 22(2), 121-126.
Boretti, A. (2023). Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe. Eur Neuropsychopharmacol , 67, 83-85.
Borovcanin, M.M., Vesic, K., Balcioglu, Y.H., Mijailović, N.R. (2022). Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution. Front Psychiatry , 13, 1052710.
Cipriani, A., Furukawa, T.A., Salanti, G., Chaimani, A., Atkinson, L.Z., Ogawa, Y., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.Lancet , 391(10128), 1357-1366.
Dąbrowska, E., Galińska-Skok, B., Waszkiewicz, N. (2021). Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19. Life (Basel ), 11(10), 1056.
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., Millan, M.J. (2010). Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov , 9(8), 628-642.
Demyttenaere, K., Corruble, E., Hale, A., Quera-Salva, M.A., Picarel-Blanchot, F., Kasper, S. (2013). A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.CNS Spectr , 18(3), 163-170.
Di Nicola, M., Pepe, M., Montanari, S., Spera, M.C., Panaccione, I., Simonetti, A., Sani, G. (2023). Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes. Eur Neuropsychopharmacol , 70, 21-28.
Dobrodeeva, V., Abdyrahmanova, A., Astafeva, D., Smirnova, D., Cumming, P., De Sousa, A., et al. (2022). Pharmacogenetic aspects of COVID-19 management and post-COVID-19 depression treatment with fluvoxamine.Psychiatr Danub , 34(Suppl 8), 25-30.
Firouzabadi, D., Kheshti, F., Abdollahifard, S., Taherifard, E., Kheshti, M.R. (2022). The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis. Health Sci Rep , 5(6), e892.
Gupta, K., Gupta, R., Bhatia, M.S., Tripathi, A.K., Gupta, L.K. (2017). Effect of agomelatine and fluoxetine on HAM-D score, serum brain-derived neurotrophic factor, and tumor necrosis factor-α level in patients with major depressive disorder with severe depression. J Clin Pharmacol , 57(12), 1519-1526.
Gupta, A., Madhavan, M.V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T.S., et al. (2020). Extrapulmonary manifestations of COVID-19.Nat Med , 26(7), 1017-1032.
Hoertel, N., Sánchez-Rico, M., Vernet, R., Beeker, N., Jannot, A.S., Neuraz, A., et al., AP-HP / Universities / INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative. (2021). Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry , 26(9), 5199-5212.
Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., et al. (2021). 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet , 397(10270), 220-232.
Hyeon, J.Y., Choi, E.Y., Choe, S.H., Park, H.R., Choi, J.I., Choi, I.S., et al. (2017). Agomelatine, a MT1/MT2 melatonergic receptor agonist with serotonin 5-HT2C receptor antagonistic properties, suppresses Prevotella intermedia lipopolysaccharide-induced production of proinflammatory mediators in murine macrophages. Arch Oral Biol , 82, 11-18.
Ivanov. S.V., Samushiya, M.A. (2014). Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study. Neuropsychiatr Dis Treat , 10, 631-639.
Kalkman, H.O., Feuerbach, D. (2016). Antidepressant therapies inhibit inflammation and microglial M1-polarization. Pharmacol Ther , 163, 82-93.
Kasper, S., Hajak, G., Wulff, K., Hoogendijk, W.J., Montejo, A.L., Smeraldi, E., et al. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry , 71(2), 109-120.
Kennedy. S.H., Avedisova, A., Belaidi, C., Picarel-Blanchot, F., de Bodinat, C. (2016). Sustained efficacy of agomelatine 10 mg, 25 mg and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol , 26, 378–389.
Kennedy, S.H., Rizvi, S.J. (2010). Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs , 24(6), 479-499.
Khraisat, B., Toubasi, A., AlZoubi, L., Al-Sayegh, T., Mansour, A. (2022). Meta-analysis of prevalence: the psychological sequelae among COVID-19 survivors. Int J Psychiatry Clin Pract , 26(3), 234-243.
Lemoine, P., Guilleminault, C., Alvarez, E. (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, ago­melatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry , 68(11), 1723–1732.
Lenze, E.J., Mattar, C., Zorumski, C.F., Stevens, A., Schweiger, J., Nicol, G.E., Miller, J.P., Yang, L., Yingling, M., Avidan, M.S., Reiersen, A.M. (2020). Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial.JAMA , 324(22), 2292-2300.
Mas, M., García-Vicente, J.A., Estrada-Gelonch, A., Pérez-Mañá, C., Papaseit, E., Torrens, M., et al. (2022). Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence. J Clin Med , 11(14), 4038.
Mazza, M.G., Zanardi, R., Palladini, M., Rovere-Querini, P., Benedetti, F. (2022) Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol , 54, 1-6.
Medvedev, V.E. (2017). Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE. Neuropsychiatr Dis Treat , 13, 1141-1151.
Medvedev, V. (2018). Efficacy and tolerability of contemporary antidepressants: results of network meta-analyses and Russian experience. Zhurnal Nevrologii i Psikhiatrii Imeni SS Korsakova , 118(11), 109‑117. (In Russ.) https://doi.org/10.17116/jnevro2018118111109
Medvedev, V.E. (2021). Anxiety and depression in COVID-19: treatment options. Neurol Neuropsychiatr Psychosomat , 13(2), 111-116. (In Russ). DOI: 10.14412/2074-2711-2021-2-111-116.
Medvedev, V.E., Retiunsky, K.Y., Ovchinnikov, A.A., Barylnik, Y.B., Shmilovich, A.A., Antokhin, E.Y., et al. (2016). Razlichiya v otsenke tyazhesti depressii vrachami i patsientami v protsesse kombinirovannoi terapii agomelatinom (mul’titsentrovoe issledovanie «EMOTsIYa») [The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study ”EMOTION”)]. Zh Nevrol Psikhiatr Im S S Korsakova , 116(11), 26-34. Russian.
Medvedev, V.E., Korovyakova, E.A., Frolova, V.I., Gushanskaya, E.V. (2019). Antidepressant therapy in patients with cardiovascular diseases. Nevrologiya, neiropsikhiatriya, psikhosomatika. Neurol.Neuropsychiatr Psychosomat , 11(1), 131–140. (Russian)
Millan, M.J. (2022). Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.Ther Adv Psychopharmacol , 12, 20451253221105128.
Molteni, R., Macchi, F., Zecchillo, C., Dell’agli, M., Colombo, E., Calabrese, F., et al. (2013). Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine. Eur Neuropsychopharmacol , 23(11), 1645-1655.
Olié, J.P., Kasper, S. (2007). Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol , 10(5), 661–673.
Ozmen, O., Topsakal, S. (2022). Preventive effect of agomelatine in lipopolysaccharide-induced pancreatic pathology. Drug Chem Toxicol , 45(1), 180-184.
Pashaei, Y. (2021). Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?J Clin Neurosci , 88, 163-172. doi: 10.1016/j.jocn.2021.03.010;
Premraj, L., Kannapadi, N.V., Briggs, J., Seal, S.M., Battaglini, D., Fanning, J., Suen, J., Robba, C., Fraser, J., Cho, S.M. (2022). Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J Neurol Sci , 434, 120162.
Quera-Salva, M.A., Hajak, G., Philip, P., Montplaisir, J., Keufer-Le Gall, S., Laredo, J., et al. (2011). Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol , 26(5), 252-262.
Renaud-Charest, O., Lui, L.M.W., Eskander, S., Ceban, F., Ho, R., Di Vincenzo, J.D., Rosenblat, J.D., Lee, Y., Subramaniapillai, M., McIntyre, R.S. (2021). Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. J Psychiatr Res , 144, 129-137.
Rogers, J.P., Chesney, E., Oliver, D., Pollak, T.A., McGuire, P., Fusar-Poli, P., Zandi, M.S., Lewis, G., David, A.S. (2020). Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry , 7(7), 611-627.
Salehinejad, M.A., Azarkolah, A., Ghanavati, E., Nitsche, M.A. (2022). Circadian disturbances, sleep difficulties and the COVID-19 pandemic.Sleep Med , 91, 246-252.
Savran, M., Aslankoc, R., Ozmen, O., Erzurumlu, Y., Savas, H.B., Temel, E.N., et al. (2020). Agomelatine could prevent brain and cerebellum injury against LPS-induced neuroinflammation in rats. Cytokine , 127, 154957.
Schou, T.M., Joca, S., Wegener, G., Bay-Richter, C. (2021). Psychiatric and neuropsychiatric sequelae of COVID-19 - A systematic review.Brain Behav Immun , 97, 328-348.
Smulevich, A.B., Andryushenko, A.V., Beskova, D.A. (2011). Therapy of nonpsychotic depression by agomelatine (Valdoxan): results of the observational multicenter study ”RHYTHM”. Psychiatr Psychopharmacother , 4, 4-12.
Stein, D.J., Khoo, J.P., Picarel-Blanchot, F., Olivier, V., Van Ameringen, M. (2021). Efficacy of agomelatine 25-50 mg for the treatment of anxious symptoms and functional impairment in generalized anxiety disorder: a meta-analysis of three placebo-controlled studies. Adv Ther , 38(3), 1567-1583.
Taylor, D., Sparshatt, A., Varma, S., Olofinjana, O. (2014). Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ , 348, g1888.
Tsygankov, B.D., Yaltonskaya, A.V., Filippskih, S.V. (2011). Valdoxan (Agomelatine) in the therapy of severe and moderate depressions of the non-psychotic level (result of the observation research TIME (VREMYA)).Rev Psychiatr Med Psychol , 1, 37-40.
University of Liverpool. COVID-19 Drug Interactions. https://www.covid19-druginteractions.org.
Volel, B.A. (2015). Safety and efficacy of agomelatine in the treatment of anxiety and depressive disorders in clinical practice (based on OCTAVA protocol). Psychiatr Psychopharmacother , 2, 9-14.
Vorob’eva, O.V. (2012). [Valdoxan in the treatment of depression in neurological practice: results of the Russian multicenter naturalistic study ”Resonance”]. Zh Nevrol Psikhiatr Im SS Korsakova , 112(9), 47-51. (Russian.)
Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J., Prescott, H.C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA , 324(8), 782-793. doi:10.1001/jama.2020.12839.
Xu, F., Wang, X., Yang, Y., Zhang, K., Shi, Y., Xia, L., et al. (2022). Depression and insomnia in COVID-19 survivors: a cross-sectional survey from Chinese rehabilitation centers in Anhui province. Sleep Med , 91, 161-165.
Yakno, N.N., Voznesenskay, T.G. (2012). Efficacy and tolerability of agomelatine (valdoxan) in the treatment of mild and moderate depressive disorders in neurological practice (results of the Russian multicenter study ”Kamerton”). Nevrologicheskyi J , 1, 43-49.
Zimmerman, M., Martinez, J.H., Young, D., Chelminski, I., Dalrymple, K. (2013). Severity classification on the Hamilton Depression Rating Scale.J Affect Disord , 150(2), 384-348.